Table 1 Comparison of redesigned HV loops to those found in vaccine candidates
V1HV | V2HV | V4HV | V5HV | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sequence | Subtype/CRF | Efficacy trials | NAAa | NPNGS | NAAa | NPNGS | NAAa | NPNGS | NAAa | NPNGS |
A244 | CRF01_AE | VAX003, RV144 | 28 (90%) | 5 | 8 (62%) | 1 | 9 (65%) | 1 | 9 (75%) | 2 |
MN | B | VAX003, VAX004, RV144 | 27 (81%) | 3 | 6 (45%) | 1 | 12 (52%) | 2 | 10 (78%) | 1 |
GNE8 | B | VAX004 | 20 (36%) | 2 | 6 (45%) | 1 | 15 (83%) | 3 | 7 (12%) | 1 |
92TH023 | CRF01_AE | RV144 | 23 (52%) | 3 | 8 (62%) | 1 | 9 (65%) | 2 | 7 (27%) | 2 |
92RW020 | A1 | HVTN505 | 9 (2%) | 2 | 8 (61%) | 1 | 12 (67%) | 3 | 7 (16%) | 1 |
HXB2 | B | HVTN505 | 21 (43%) | 2 | 6 (45%) | 1 | 15 (83%) | 2 | 8 (36%) | 1 |
97ZA012 | C | HVTN505 | 15 (23%) | 2 | 11 (76%) | 2 | 2 (9%) | 0 | 8 (44%) | 0 |
96ZM651 | C | HVTN702 | 26 (86%) | 4 | 14 (93%) | 2 | 6 (27%) | 1 | 12 (92%) | 2 |
TV1 | C | HVTN702 | 33 (98%) | 4 | 6 (25%) | 0 | 13 (87%) | 2 | 9 (60%) | 2 |
1086 | C | HVTN702 | 12 (12%) | 1 | 9 (62%) | 1 | 12 (79%) | 3 | 10 (76%) | 2 |
Mosaic1.Env | – | HVTN705, HVTN706 | 25 (74%) | 3 | 8 (61%) | 2 | 16 (93%) | 3 | 8 (43%) | 1 |
Mosaic2.Env | – | HVTN705, HVTN706 | 21 (45%) | 3 | 16 (97%) | 2 | 9 (33%) | 2 | 11 (89%) | 1 |
CH505 | C | – | 12 (12%) | 2 | 6 (25%) | 1 | 15 (94%) | 3 | 6 (6%) | 1 |
WITO | B | – | 19 (26%) | 3 | 8 (68%) | 1 | 11 (37%) | 2 | 8 (36%) | 2 |
DU422 | C | – | 21 (62%) | 3 | 10 (70%) | 1 | 9 (49%) | 2 | 7 (18%) | 1 |
BG505 | A1 | – | 13 (8%) | 2 | 14 (94%) | 2 | 14 (83%) | 3 | 8 (43%) | 1 |
JR-FL | B | - | 19 (26%) | 3 | 6 (45%) | 1 | 11 (37%) | 2 | 8 (36%) | 1 |
B_2010sb | B | - | 12 (4%) | 1 | 4 (11%) | 1 | 11 (37%) | 3 | 7 (12%) | 2 |
C_2010sb | C | - | 13 (16%) | 1 | 5 (8%) | 1 | 11 (69%) | 3 | 7 (18%) | 1 |
01_AE_2010s.1b | CRF01_AE | - | 9 (1%) | 1 | 5 (12%) | 1 | 11 (84%) | 3 | 7 (27%) | 2 |
01_AE_2010s.2b | CRF01_AE | - | 19 (8%) | 1 | 5 (12%) | 1 | 11 (84%) | 3 | 7 (27%) | 2 |